January 15, 2024

MultiplexDX visited its long-term cooperation partner, the Eastern Slovak Oncology Institute in Kosice

As we aim to approach more and more patients with our Multiplex8+ test - we appreciate our long-term cooperation partner, Eastern Slovak Oncology Institute in Kosice, which helps us to pilot a small prospective study and deliver more accurate results for patients with breast cancer.

Our Multiplex8+ diagnostic test has been successfully deployed for the first 30 patients diagnosed with breast cancer. Most of the patients came from the Eastern Slovak Oncology Institute in Kosice (VOU).

For more information, go to https://lnkd.in/dq27isa7.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News